Login to Your Account



Roche Licenses Rights To IL-15 Preclinical Program From Cardion

By Aaron Lorenzo


Wednesday, July 23, 2003
Hoffmann-La Roche Inc. could find itself paying up to $90 million or more for a preclinical research program with transplant rejection and rheumatoid arthritis applications. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription